Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T Cells

Journal of Virology

Volumn 87, Issue 5, 2013, Pages 2628-2638

  Kløverpris, Henrik N ^a   Payne, Rebecca P ^a   Sacha, Jonah B ^b   Rasaiyaah, Jane T ^c   Chen, Fabian ^d   Takiguchi, Masafumi ^e   Yang, Otto O ^f   Towers, Greg J ^c   Goulder, Philip ^a   Prado, Julia G ^g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^e KUMAMOTO UNIVERSITY   (Japan)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA B ANTIGEN; T LYMPHOCYTE RECEPTOR;

ALLELE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KINETICS; LYMPHOCYTE ACTIVATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRAL CLEARANCE; VIRUS PARTICLE; VIRUS REPLICATION;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITOPES; EPITOPES, T-LYMPHOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION; VIRUS REPLICATION;

EID: 84874671204     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02131-12     Document Type: Article

References (58)

1. Virgin HW, Walker BD. 2010. Immunology and the elusive AIDS vaccine. Nature 464:224-231.
2. Walker BD, Burton DR. 2008. Toward an AIDS vaccine. Science 320: 760-764.
3. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23.
4. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia HM, Walker BD, Goulder PJ. 2004. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432:769-775.
5. Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H, Walker BD, Heckerman D, Goulder PJ. 2010. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J. Virol. 84:9879-9888.
6. O'Brien SJ, Gao X, Carrington M. 2001. HLA and AIDS: a cautionary tale. Trends Mol. Med. 7:379-381.
7. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13:46-53.
8. Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, Ndung'u T, Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter E. 2009. Evolution of HLA-B*5703 HIV-1 escape mutations in HLAB* 5703-positive individuals and their transmission recipients. J. Exp. Med. 206:909-921.
9. Schneidewind A, Brockman MA, Yang R, Adam RI, Li B, Le Gall S, Rinaldo CR, Craggs SL, Allgaier RL, Power KA, Kuntzen T, Tung CS, LaBute MX, Mueller SM, Harrer T, McMichael AJ, Goulder PJ, Aiken C, Brander C, Kelleher AD, Allen TM. 2007. Escape from the dominant HLA-B27-restricted cytotoxic T-lymphocyte response in Gag is associatedwith a dramatic reduction in human immunodeficiency virus type 1 replication. J. Virol. 81:12382-12393.
10. +T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204:2473-2485.
11. + T cells. Blood 107:4781-4789.
12. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, Roederer M, Rowland-Jones SL, Koup RA. 2008. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur. J. Immunol. 38:350-363.
13. Ferre AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF, Jr, Martin JN, Deeks SG, Shacklett BL. 2009. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 113:3978-3989.
14. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO. 2007. Epitopedependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J. Virol. 81:4973-4980.
15. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, Barre-Sinoussi F, Delfraissy JF, Sinet M, Pancino G, Venet A. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104:6776-6781.
16. Saez-Cirion A, Sinet M, Shin SY, Urrutia A, Versmisse P, Lacabaratz C, Boufassa F, Avettand-Fenoel V, Rouzioux C, Delfraissy JF, Barre-Sinoussi F, Lambotte O, Venet A, Pancino G. 2009. Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182:7828-7837.
17. Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. 2003. Impacts of avidity and specificity on the antiviral efficiency of HIV-1-specific CTL. J. Immunol. 171:3718-3724.
18. + T cells recognize Vpr-and Rev-derived epitopes early after infection. J. Virol. 84:10907-10912.
19. + T lymphocytes recognize infected cells before AIDSvirus integration and viral protein expression. J. Immunol. 178:2746-2754.
20. + T cells recognize simian immunodeficiency virus-infected cells prior to Nef-mediated major histocompatibility complex class I downregulation. J. Virol. 81:11703-11712.
21. + T-cell epitopes derived from the same viral protein. J. Virol. 82:9293-9298.
22. Ali A, Lubong R, Ng H, Brooks DG, Zack JA, Yang OO. 2004. Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J. Virol. 78:561-567.
23. van Baalen CA, Guillon C, van Baalen M, Verschuren EJ, Boers PH, Osterhaus AD, Gruters RA. 2002. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur. J. Immunol. 32:2644-2652.
24. + T cells. J. Virol. 84: 10543-10557.
25. Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, Mncube Z, Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela P, Walker BD, Goulder PJ. 2007. Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLAB* 5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. J. Virol. 81:8346-8351.
26. Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, Walker BD, Goulder PJ. 2004. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-termnonprogressing child. J. Virol. 78:8927-8930.
27. Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh K, Korber BT, Walker BD. 2001. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412:334-338.
28. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S. 1997. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:212-217.
29. Shimizu Y, DeMars R. 1989. Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. J. Immunol. 142:3320-3328.
30. +T-cell epitope in p1 Gag protein. J. Virol. 83:1018-1025.
31. Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, Kazanjian P, Quinones-Mateu ME. 2006. Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J. Virol. Methods 136:102-117.
32. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15:871-875.
33. Bainbridge JW, Stephens C, Parsley K, Demaison C, Halfyard A, Thrasher AJ, Ali RR. 2001. In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther. 8:1665-1668.
34. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272:263-267.
35. Besnier C, Takeuchi Y, Towers G. 2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. U. S. A. 99:11920-11925.
36. Sacha JB, Watkins DI. 2010. Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat. Protoc. 5:239-246.
37. Freel SA, Lamoreaux L, Chattopadhyay PK, Saunders K, Zarkowsky D, Overman RG, Ochsenbauer C, Edmonds TG, Kappes JC, Cunningham CK, Denny TN, Weinhold KJ, Ferrari G, Haynes BF, Koup RA, Graham BS, Roederer M, Tomaras GD. 2010. Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. J. Virol. 84:4998-5006.
38. Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. 2003. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77:2081-2092.
39. Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, Stone DR, Kalams SA, Trocha A, Addo MM, Goulder PJ, Walker BD. 2003. Comparison of overlapping peptide sets for detection of antiviral CD8 and CD4 T cell responses. J. Immunol. Methods 275:19-29.
40. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, Moysey R, Cameron BJ, Vuidepot A, Purbhoo MA, Cole DK, Phillips RE, June CH, Jakobsen BK, Sewell AK, Riley JL. 2008. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. Nat. Med. 14:1390-1395.
41. Ranki A, Lagerstedt A, Ovod V, Aavik E, Krohn KJ. 1994. Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139:365-378.
42. Kafri T, Morgan D, Krahl T, Sarvetnick N, Sherman L, Verma I. 1998.Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl. Acad. Sci. U. S. A. 95:11377-11382.
43. Riddell SR, Rabin M, Geballe AP, Britt WJ, Greenberg PD. 1991. Class I MHC-restricted cytotoxic T lymphocyte recognition of cells infected with human cytomegalovirus does not require endogenous viral gene expression. J. Immunol. 146:2795-2804.
44. Yewdell JW, Bennink JR, Hosaka Y. 1988. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 239:637-640.
45. Yewdell JW, Nicchitta CV. 2006. The DRiP hypothesis decennial: support, controversy, refinement and extension. Trends Immunol. 27:368-373.
46. Hahn S, Setz C, Wild J, Schubert U. 2011. The PTAP sequence within the p6 domain of human immunodeficiency virus type 1 Gag regulates its ubiquitination and MHC class I antigen presentation. J. Immunol. 186: 5706-5718.
47. + T-cell epitopes. J. Virol. 81:3667-3672.
48. Chen DY, Balamurugan A, Ng HL, Cumberland WG, Yang OO. 2012. Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. Blood 120:100-111.
49. Chen DY, Balamurugan A, Ng HL, Yang OO. 2011. Antiviral activity of human immunodeficiency virus type 1 Gag-specific cytotoxic T lymphocyte targeting is not necessarily intrinsically superior to envelope targeting. J. Virol. 85:2474-2478.
50. + T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. U. S. A. 106:9791-9796.
51. +T cells in vivo: the key to rational vaccine design. Annu. Rev. Immunol. 23:651-682.
52. Yewdell JW, Reits E, Neefjes J. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3:952-961.
53. Herberts CA, Neijssen JJ, de Haan J, Janssen L, Drijfhout JW, Reits EA, Neefjes JJ. 2006. Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation. J. Immunol. 176:2697-2701.
54. Jacks T, Power MD, Masiarz FR, Luciw PA, Barr PJ, Varmus HE. 1988. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331:280-283.
55. Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. 2004. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J. Exp. Med. 199:283-293.
56. Buseyne F, Le Gall S, Boccaccio C, Abastado JP, Lifson JD, Arthur LO, Riviere Y, Heard JM, Schwartz O. 2001. MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat. Med. 7:344-349.
57. Schaller T, Ocwieja KE, Rasaiyaah J, Price AJ, Brady TL, Roth SL, Hue S, Fletcher AJ, Lee K, KewalRamani VN, Noursadeghi M, Jenner RG, James LC, Bushman FD, Towers GJ. 2011. HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathog. 7:e1002439. doi:10.1371/journal.ppat .1002439.
58. Prado JG, Carrillo J, Blanco-Heredia J, Brander C. 2011. Immune correlates of HIV control. Curr. Med. Chem. 18:3963-3970.